000 03587nam a22004935i 4500
001 978-1-4614-6543-0
003 DE-He213
005 20140220082825.0
007 cr nn 008mamaa
008 130228s2013 xxu| s |||| 0|eng d
020 _a9781461465430
_9978-1-4614-6543-0
024 7 _a10.1007/978-1-4614-6543-0
_2doi
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a614.5999
_223
100 1 _aAptsiauri, Natalia.
_eauthor.
245 1 0 _aMHC Class I Antigens In Malignant Cells
_h[electronic resource] :
_bImmune Escape And Response To Immunotherapy /
_cby Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera.
264 1 _aNew York, NY :
_bSpringer New York :
_bImprint: Springer,
_c2013.
300 _aVIII, 51 p. 17 illus., 14 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aSpringerBriefs in Cancer Research ;
_v6
505 0 _aOverview of MHC Class I Antigens -- HLA Class I Expression In Human Cancer -- MHC Class I Expression In Experimental Mouse Models Of Cancer: Immunotherapy Of Tumors With Different MHC-I Expression Patterns -- Potential Therapeutic Approaches For Increasing Tumor Immunogenicity By Upregulation Of Tumor HLA Class I Expression -- Conclusion.
520 _aAbnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy.  Precise identification of the mechanism leading to MHC class I defects  will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy.  
650 0 _aMedicine.
650 0 _aOncology.
650 0 _aImmunology.
650 1 4 _aBiomedicine.
650 2 4 _aCancer Research.
650 2 4 _aImmunology.
650 2 4 _aMolecular Medicine.
700 1 _aGarcia-Lora, Angel Miguel.
_eauthor.
700 1 _aCabrera, Teresa.
_eauthor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781461465423
830 0 _aSpringerBriefs in Cancer Research ;
_v6
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-4614-6543-0
912 _aZDB-2-SBL
999 _c95697
_d95697